Skip to content

Study · Measured the body's own peptide · 1986

3 results

Vasoactive intestinal polypeptide immunopositive neurons in the paraventricular nucleus of homozygous Brattleboro rats.

Mezey E

Neuroendocrinology1 Jan 1986Cited by 10 (Europe PMC)

PMID3510403 (opens in a new tab)DOI10.1159/000124254 (opens in a new tab)PepBankPUB-03510403
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In colchicine-treated vasopressin-deficient Brattleboro rats, the body's own VIP was found in cell bodies of the hypothalamic paraventricular nucleus.

    In plain wordsIn vasopressin-deficient rats, the body's own VIP was found in a group of brain cells in the hypothalamus.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP-positive cell bodies in the paraventricular nucleus of Brattleboro rats
    Study

    ratn: not reported in source

    Brattleboro (vasopressin-deficient) rat, hypothalamic paraventricular nucleus
    Outcome group
    Endogenous peptide levels · Nervous system and cognition

    Source sentences

    Summary
    Colchicine treatment reveals a population of vasoactive intestinal polypeptide (VIP) positive cell bodies in the hypothalamic paraventricular nucleus (PVN) of the vasopressin-deficient Brattleboro rat.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In colchicine-treated Long-Evans rats, VIP-immunoreactive cell bodies in the paraventricular nucleus could not be detected, unlike in Brattleboro rats.

    In plain wordsIn normal Long-Evans rats, the body's own VIP could not be detected in these brain cells, unlike in Brattleboro rats.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP-positive perikarya in the paraventricular nucleus of Long-Evans rats
    Study

    ratn: not reported in source

    Brattleboro (vasopressin-deficient) rat, hypothalamic paraventricular nucleus
    Comparator
    Brattleboro rats
    Outcome group
    Endogenous peptide levels · Nervous system and cognition

    Source sentences

    Summary
    These immunoreactive perikarya in the PVN cannot be detected in colchicine-treated Long-Evans animals.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Other

    In Brattleboro rats given vasopressin, the number of VIP-immunopositive cell bodies in the paraventricular nucleus decreased significantly.

    In plain wordsIn vasopressin-deficient rats, giving vasopressin lowered the number of brain cells holding the body's own VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseNumber of VIP-positive cell bodies after vasopressin
    Study

    ratn: not reported in source

    Brattleboro (vasopressin-deficient) rat, hypothalamic paraventricular nucleus
    Outcome group
    Endogenous peptide levels · Nervous system and cognition

    Source sentences

    Summary
    When Brattleboro rats are administered vasopressin, there is a significant decrease in the number of VIP-immunopositive cell bodies in the PVN.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.